The Asian Scientist 100
Long Ran
Institution
University of Science and Technology of China
Country
China
Field
Chemistry
Long won the 2017 L’Oréal UNESCO For Women in Science International Rising Talent award for her research on photocatalysts for carbon dioxide reduction.
(Photo: L’oréal Foundation)
AWARDS
- 2017 LOréal-UNESCO For Women in Science International Rising Talent Award
Related articles
Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma
U.S. biotech Sagent Pharma will acquire the remaining 50 percent interest of the Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited joint venture.
Taiwan & Mexico Launch Astronomical Observation Project, TAOS-2
A collaboration between Taiwan and Mexico aims to build a new observatory in California that will study the Solar System beyond Neptune.
Bacteria Develop Resistance To Antimicrobial Nanosilver, Study
Overexposure to silver nanoparticles may cause other potentially harmful bacteria to rapidly adapt and flourish, says a new study.
H7N9 Genes Originated From Four Sources: Lancet Study
The novel avian influenza A H7N9 virus might have evolved from at least four origins, say Chinese researchers.
Tackle Myopia By Getting Children Out-Of-Doors, Studies Say
Spending more time outdoors may help prevent or minimize nearsightedness in children, scientists say.
Family Planning Spurs Development In Asia
Family planning is central to national economic development in Asia, writes Amy Tsui, Director of the Bill and Melinda Gates Institute of Population and Reproductive Health.
Pressure In Philippines To End Ban On Formula Milk Aid
The infant formula industry is pushing through legislative changes that will allow formula donations in future emergencies.
Kiwi Duets Are Sung In Perfect Harmony
A group of researchers in New Zealand have discovered that kiwis produce calls in harmony with each other by using a previously unknown form of vocal cooperation.
5 Take-Home Points From India’s Historic Novartis Patent Case
The Indian Supreme Court ruling dismissing a patent application by Novartis for a new version of its leukemia drug raises five important points, writes Arvind Subramanian.